Medical Device Giant Solventum Sells $4.1B Filtration Business to Thermo Fisher in Debt-Reduction Move

Author: Yu Bai

Yesterday (February 25, 2025), medical device giant Solventum (Chinese name: Shu Wanuo) officially announcedAt US$4.1 billion (approximately RMB29.8 billion) to sell its purification and filtration business to Thermo Fisher Scientific.

Source: Reuters

It is worth noting that,This is a major investment restructuring.Solventum's current market value is approximately $12.8 billion (equivalent to about RMB92.9 billion），MeansThis transaction accounts for up to 32% of the company's total value.。

In addition, this transactionThe estimated $3.4 billion in net proceeds will be used primarily to pay down debt, significantly improving the capital structure of this new giant.

Solventum was spun off from 3M and independently listed in April last year, as per the previous year's financial report.Exceeding 8.2 billion US dollars (equivalent to approximately RMB59.3 billion yuan) Revenue,OwnMore than 22,000 employees 。

Overview of Solventum's Business Segments (Medical Surgery, Dentistry, Health Information Systems, Filtration and Purification) Source: Official Document

In terms of status,This salePurification and Filtration Business isOne of the four major business segments of SolventumIn 2024, this business generated approximately US$1 billion (equivalent to RMB7.2 billion) of income.

This segment of the business primarily provides filters and membrane components, widely used in biopharmaceuticals, advanced medical technologies, microelectronics manufacturing, food and beverage processing, as well as the production of purer and safer drinking water.

Solventum Purification and Filtration Business Structure Image Source: Official Document

Solventum (formerly the medical business of 3M) simplified a three-step filtration process into a single step, increasing process yield from 85% to 95%.

The transaction is expected to be completed by the end of 2025, subject to customary closing conditions and regulatory approvals. Upon completion, the purification and filtration business will become part of Thermo Fisher Scientific's Life Sciences Solutions segment.

Thermo Fisher Scientific President and CEO Marc Casper said in a press release, "The addition of the Solventum business aligns with our companyWith excellent strategic alignment, which will create tremendous value for our customers and shareholders."

Solventum officials plan to further discuss the sale on tomorrow’s (February 27) company earnings call.

The market seems to welcome its recent business divestiture, as the news was well-received after the announcement.Solventum's stock price surged over 9%,Thermo Fisher Scientific's stock price remained basically flat.

Interestingly, Solventum announced a major deal within less than 10 months of its independent listing, coinciding with the eve of its first Investor Day. CEO Bryan Hanson’s strategic transformation appears particularly urgent.

This saleFilterThe business is the most promising sector among Solventum's four major business segments., and is likely to receive a higher premium valuation in the future due to its applications in high-growth sectors such as biopharmaceutical manufacturing and microelectronics.

And now this new giantSacrificed diversification and stable revenue streams in exchange for increased financial flexibility and focused investment in the remaining core businesses.It is also a kind of helpless trade-off and choice.

Despite its "illustrious origin," inheriting the vast business landscape of 3M Healthcare, and gathering numerous top talents from leading companies such as Medtronic, Zimmer Biomet, and Insulet, Solventum, which started on a high note, still faces considerable challenges.

In addition to facing huge debts, its cost control ability seems to have declined. In the latest financial report quarter published at the end of last year, itsOperating Profit MarginDecreased by more than 10% compared to the same period last year.CEO Hanson candidly stated, "WeDoes not deny that income growth remains below market levels.。”

For the quarter ended September 30 last year, Solventum's adjusted net profit was $285 million, with sales of $2 billion.Compared to its performance as one of the four major divisions under 3M, its adjusted profit has plummeted by more than 40%.。

Under the severe situation, in December last year,Solventum Announces Restructuring, Officially Launches Layoffs; Behind Several Drastic Cuts, Deeper Reasons Are Coming to Light.

It is worth mentioning that, earlier as the 3M medical department, the growth of this part of the business was already less than ideal.

In the annual report previously disclosed on 3M's official website, all four segments of 3M showed negative growth, with the healthcare business experiencing the smallest decline but still failing to achieve positive revenue.

During the 2016 Investor Day, then-CEO Inge Thulin told investors that organic local currency sales in the healthcare sector would grow between 2016 and 2020.(Organic growth excluding the impact of exchange rates and mergers & acquisitions)Will grow at an average rate of 4% to 6%.

But the fact is:For many years, 3M's medical business has failed to approach this figure (see table below).Its outstanding performance in 2021 was attributed to the rebound from the pandemic lockdowns that affected 2020.

At that time, the decision to spin off the healthcare sector for an IPO was also a necessary move to reduce the burden, accelerate growth, and expedite financing.

In addition to the previous weak growth,The future market growth potential is also an important reference for exploring the company's potential.

After this business divestiture, Solventum's core revenue still relies on traditional surgical and dressing businesses. Although it has certain advantages, the overall growth rate of related businesses has slowed to single digits, which contrasts sharply with the double-digit industry growth rates in cardiovascular, diabetes, and other fields.

In other words, the company still faces considerable pressure for future growth.

Looking at the top medical device companies, the current transformation focuses more on high-potential fields such as cardiovascular, electrophysiology, and diabetes, while老牌 businesses with relatively slower growth, like surgery, are being streamlined. For instance, Johnson & Johnson.

Although Solventum is currently working hard on its reorganization and reform, the company is still in the transition period with 3M, which will last for 12 to 24 months.

Business transition and divestiture restructuring must go hand in hand, inevitably leading to a period of pain.

Perhaps as its logo suggestsThe meaning represented by it is average, SolventumThe road to forward exploration is far from reaching its "end."

Amid the global "de-conglomeratization wave," "slimming down and reducing burdens" seems to have become the go-to strategy for giants seeking a breakthrough.But the change in form is not the hardest part; whether the reshuffle can effectively unleash innovative vitality still needs to be tested by time.